Printer Friendly

Byrd Named CEO at Healthcare Technology Firm CaptureRx.

M2 PHARMA-September 8, 2016-Byrd Named CEO at Healthcare Technology Firm CaptureRx

(C)2016 M2 COMMUNICATIONS

- US-based healthcare technology firm CaptureRx's president, Dave Byrd, has been appointed CEO, the company said.

Byrd succeeds former CEO, Chris Hotchkiss, who remains chairman of CaptureRx's board of directors.

Since joining CaptureRx in 2014, Byrd has served in key leadership roles as the company's chief financial officer, chief operations officer and president.

During his tenure, the company's customer base has expanded to more than 500 covered entities and nearly 3,000 pharmacies.

Byrd has a proven record of success leading organisational transformations throughout a career that spans nearly three decades.

As a senior executive with Diebold, he managed multim dollar operations and a startup division that launched the company into the healthcare sector.

Byrd has also made significant growth contributions as a financial executive at other leading technology companies, including IBM and Electronic Data Systems.

Working in partnership with Hotchkiss, Byrd helped lead the growth of the CaptureRx team from 75 employees to more than 120 over the past two years, adding a senior leadership team to guide process improvements and create strategic partnerships to fuel continued growth.

Under the direction of Hotchkiss and Byrd, the team has concentrated on expanding the company's specialty pharmacy relationships, optimizing the company's cash card offering, launching a 340B solution for Medicaid managed care, and developing a split-billing solution.

Founded in 2000, San Antonio-based CaptureRx is a 340B solution provider. Its solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 8, 2016
Words:278
Previous Article:Neuravi Launches EmboTrap II Stent Retriever in Europe.
Next Article:Tonix Pharmaceuticals halts development of TNX-102 SL.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters